The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The effect of tumor response on quality of life (QoL) in patients with KRAS wild-type metastatic colorectal cancer (mCRC): Analysis from the CRYSTAL study.
I. Griebsch
Employment or Leadership Position - Merck KGaA
I. Lang
No relevant relationships to disclose
U. Sartorius
Employment or Leadership Position - Merck KGaA
E. Van Cutsem
Consultant or Advisory Role - Merck Serono
Research Funding - Merck Serono